Free Trial
→ ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
$3.18
$3.17
$1.10
▼
$4.18
$819.45M1.0714.72 million shsN/A
Innoviva, Inc. stock logo
INVA
Innoviva
$21.21
+1.6%		$20.96
$16.52
▼
$25.15
$1.53B0.381.04 million shs507,532 shs
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
0.00%0.00%0.00%0.00%+23.74%
Innoviva, Inc. stock logo
INVA
Innoviva
0.00%+3.46%+2.86%-4.63%+22.11%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
$3.18
$3.17
$1.10
▼
$4.18
$819.45M1.0714.72 million shsN/A
Innoviva, Inc. stock logo
INVA
Innoviva
$21.21
+1.6%		$20.96
$16.52
▼
$25.15
$1.53B0.381.04 million shs507,532 shs
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
0.00%0.00%0.00%0.00%+23.74%
Innoviva, Inc. stock logo
INVA
Innoviva
0.00%+3.46%+2.86%-4.63%+22.11%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
2.00
Hold$5.5474.21% Upside
Innoviva, Inc. stock logo
INVA
Innoviva
2.67
Moderate Buy$39.2585.05% Upside

Current Analyst Ratings Breakdown

Latest ESPR and INVA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/24/2026
Innoviva, Inc. stock logo
INVA
Innoviva
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy (B-) ➝ Hold (C+)
9/23/2026
Innoviva, Inc. stock logo
INVA
Innoviva
Oppenheimer Holdings, Inc. logo
Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$35.00
9/9/2026
Innoviva, Inc. stock logo
INVA
Innoviva
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold (C+) ➝ Buy (B-)
8/31/2026
Innoviva, Inc. stock logo
INVA
Innoviva
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong Sell ➝ Hold
8/11/2026
Innoviva, Inc. stock logo
INVA
Innoviva
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy (B) ➝ Hold (C+)
8/7/2026
Innoviva, Inc. stock logo
INVA
Innoviva
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$36.00 ➝ $34.00
7/31/2026
Innoviva, Inc. stock logo
INVA
Innoviva
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold ➝ Strong Sell
(Data available from 10/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
$403.14M2.03N/AN/A($1.26) per share-2.52
Innoviva, Inc. stock logo
INVA
Innoviva
$411.33M3.73$5.03 per share4.22$15.71 per share1.35
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
-$22.68M-$0.06N/A14.45N/A0.12%-0.14%0.12%N/A
Innoviva, Inc. stock logo
INVA
Innoviva
$271.17M$4.105.179.963.0681.19%28.03%20.19%11/4/2026 (Estimated)

Latest ESPR and INVA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/4/2026Q3 2026
Innoviva, Inc. stock logo
INVA
Innoviva
$0.49N/AN/AN/A$115.31 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
N/AN/AN/AN/AN/A
Innoviva, Inc. stock logo
INVA
Innoviva
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
N/A
1.53
1.18
Innoviva, Inc. stock logo
INVA
Innoviva
0.21
16.01
15.18

Institutional Ownership

CompanyInstitutional Ownership
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
47.39%
Innoviva, Inc. stock logo
INVA
Innoviva
99.12%

Insider Ownership

CompanyInsider Ownership
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
1.60%
Innoviva, Inc. stock logo
INVA
Innoviva
2.01%
CompanyEmployeesShares OutstandingFree FloatOptionable
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
200257.69 million253.57 millionOptionable
Innoviva, Inc. stock logo
INVA
Innoviva
15972.25 million70.79 millionOptionable

Recent News About These Companies

Analyzing Innoviva (NASDAQ:INVA) & Assembly Biosciences (NASDAQ:ASMB)
 |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31107656
Innoviva, Inc. (INVA) - What Are Analysts Thinking About This Stock?
October 10 at 4:13 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-innoviva-inc-inva-what-are-analysts-thinking-about-this-stock-2026-10-10/
Is Innoviva (INVA) Undervalued As Zacks Flags Its Value Appeal?
October 8 at 7:17 PM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/innoviva-inva-undervalued-zacks-flags-191909404.html
INVA vs. MRK: Which Stock Is the Better Value Option?
October 8 at 12:40 PM  |  zacks.comhttps://www.zacks.com/stock/news/3002992/inva-vs-mrk-which-stock-is-the-better-value-option?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_3-3002992
5 Attractive Low Price-to-Sales Stocks With Promising Upside Potential
October 8 at 10:56 AM  |  zacks.comhttps://www.zacks.com/stock/news/3002920/5-attractive-low-price-to-sales-stocks-with-promising-upside-potential?cid=cs-stocknewsapi-ft-analyst_blog|rw-3002920
Should Value Investors Buy Innoviva (INVA) Stock?
October 8 at 10:41 AM  |  zacks.comhttps://www.zacks.com/stock/news/3002733/should-value-investors-buy-innoviva-inva-stock?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_2-3002733
Russian plague outbreak could boost these under-the-radar pharma stocks
October 5, 2026  |  invezz.comI
Innoviva, Inc. $INVA Shares Newly Bought by Bank of America Corp DE
October 2, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-innoviva-inc-inva-shares-newly-bought-by-bank-of-america-corp-de-2026-10-02/
Zymeworks Updates Annual Financial Targets After Finalizing Theravance Biopharma Deal
September 28, 2026  |  benzinga.comhttps://www.benzinga.com/trading-ideas/movers/26/09/62030831/zymeworks-updates-annual-financial-targets-after-finalizing-theravance-biopharma-deal
Theravance Biopharma Completes Merger and Plans Nasdaq Delisting
September 23, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/theravance-biopharma-completes-merger-and-plans-nasdaq-delisting?utm_source=marketbeat.com&utm_medium=referral
Zymeworks Closes Theravance Acquisition and CVR Financing
September 23, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/zymeworks-closes-theravance-acquisition-and-cvr-financing?utm_source=marketbeat.com&utm_medium=referral
Oppenheimer Assumes Inova Technology, Inc. (INVA) at Outperform
September 23, 2026  |  streetinsider.comhttps://www.streetinsider.com/Analyst+Comments/Oppenheimer+Assumes+Inova+Technology%2C+Inc.+%28INVA%29+at+Outperform/27093090.html
Oppenheimer Upgrades Innoviva to Outperform From Neutral, $35 Price Target
September 23, 2026  |  marketscreener.comM
Innoviva (NASDAQ:INVA) Receives "Outperform" Rating from Oppenheimer
September 23, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-innoviva-nasdaq-inva-receives-outperform-rating-from-oppenheimer-2026-09-23/
Bank of America Corp DE Invests $37.87 Million in Innoviva, Inc. $INVA
September 22, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-america-corp-de-invests-3787-million-in-innoviva-inc-inva-2026-09-22/
Reviewing Innoviva (NASDAQ:INVA) and 60 Degrees Pharmaceuticals (NASDAQ:SXTP)
September 16, 2026  |  defenseworld.netD
Innoviva, Inc. (NASDAQ:INVA) Given Average Recommendation of "Moderate Buy" by Brokerages
September 15, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-innoviva-inc-nasdaq-inva-given-average-recommendation-of-moderate-buy-by-brokerages-2026-09-15/
Baird Financial Group Inc. Makes New $6.23 Million Investment in Innoviva, Inc. $INVA
September 15, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-baird-financial-group-inc-makes-new-623-million-investment-in-innoviva-inc-inva-2026-09-15/
Theravance Biopharma issues disclosures amid Zymeworks merger
September 10, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/theravance-biopharma-issues-disclosures-amid-zymeworks-merger?utm_source=marketbeat.com&utm_medium=referral
Theravance Biopharma details Phase 3 ampreloxetine data
August 25, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/theravance-biopharma-details-phase-3-ampreloxetine-data?utm_source=marketbeat.com&utm_medium=referral
Innoviva Specialty Therapeutics’ Antimicrobial Therapies, XACDURO®, ZEVTERA® and NUZOLVENCE® Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product ...
August 11, 2026  |  uk.finance.yahoo.comhttps://uk.finance.yahoo.com/news/innoviva-specialty-therapeutics-antimicrobial-therapies-200500637.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Esperion Therapeutics stock logo

Esperion Therapeutics NASDAQ:ESPR

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Innoviva stock logo

Innoviva NASDAQ:INVA

$21.21 +0.34 (+1.63%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$21.09 -0.12 (-0.57%)
As of 10/9/2026 07:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas